IL1B and Hepatitis: Pretreatment with recombinant human IL-1 receptor antagonist (rhIL-1Ra), which blocks IL-1 activity post-ConA liver injury, greatly suppressed hepatitis through reduced TNF and IL-17 secretion and decreased inflammatory cell infiltration [219].